<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 7.2 - Severe Asthma | MD3 SCP Cases</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 7.2 - Severe Asthma | MD3 SCP Cases">
  <meta name="description" content="Emergency case study on severe asthma exacerbation for medical students.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:url" content="https://md3-scp.netlify.app/cases/case7_2.html">
  <meta property="og:title" content="Case 7.2 - Severe Asthma">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="Emergency case study on severe asthma exacerbation for medical students.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">

  <!-- Twitter -->
  <meta property="twitter:card" content="summary">
  <meta property="twitter:title" content="Case 7.2 - Severe Asthma">
  <meta property="twitter:description" content="Emergency case study on severe asthma exacerbation for medical students.">
  <meta property="twitter:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">

  <link rel="stylesheet" href="../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 7.2 – Severe Asthma</h1>
    <p class="meta"><strong>Category:</strong> Respiratory System | <strong>Discipline:</strong> Medicine | <strong>Setting:</strong> Emergency Department</p>

    <h2>Case</h2>
    <p>Adam Henshaw, aged 48 years, presents via ambulance from work. He is pale and unwell and short of breath. On examination his respiratory rate is 26/minute, his heart rate is 120/min. and he has difficulty speaking. The ambulance officers tell you he has a history of asthma and his PEF is 33% of predicted.</p>

    <h2>Questions</h2>

    <div class="question">
      <strong>1. What are the features of acute severe asthma?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p>Acute severe asthma is a medical emergency that requires prompt recognition and treatment. The following features indicate severe asthma:</p>

        <p><strong>Clinical Features:</strong></p>
        <ul>
          <li><strong>Peak Expiratory Flow (PEF):</strong> 33-50% of predicted or best</li>
          <li><strong>Respiratory Rate:</strong> ≥25 breaths per minute</li>
          <li><strong>Heart Rate:</strong> ≥110 beats per minute</li>
          <li><strong>Speech:</strong> Inability to complete sentences in one breath</li>
        </ul>

        <p><strong>Life-Threatening Features (require immediate ICU assessment):</strong></p>
        <ul>
          <li><strong>PEF:</strong> \&lt;33% of predicted or best</li>
          <li><strong>SpO₂:</strong> \&lt;92% on room air</li>
          <li><strong>Silent chest, cyanosis, or feeble respiratory effort</strong></li>
          <li><strong>Bradycardia, dysrhythmia, or hypotension</strong></li>
          <li><strong>Exhaustion, confusion, or reduced consciousness</strong></li>
        </ul>

        <p><strong>Near-Fatal Asthma:</strong></p>
        <ul>
          <li>Raised PaCO₂ and/or requiring mechanical ventilation with raised inflation pressures</li>
        </ul>

        <p><em>Note: The absence of any of these features does not exclude a diagnosis of severe asthma. Clinical judgment is essential.</em></p>
      </div>
    </div>

    <div class="question">
      <strong>2. Summarise your approach to the management of acute severe asthma.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p>Management of acute severe asthma requires immediate intervention with a structured approach:</p>

        <p><strong>Immediate Management (First Hour):</strong></p>

        <p><strong>1. Oxygen Therapy:</strong></p>
        <ul>
          <li>High-flow oxygen via face mask to maintain SpO₂ 94-98%</li>
          <li>Do not withhold oxygen for fear of hypercapnia</li>
        </ul>

        <p><strong>2. Bronchodilators:</strong></p>
        <ul>
          <li><strong>β₂-agonist:</strong> Salbutamol 5mg via oxygen-driven nebuliser, repeat every 15-20 minutes or consider continuous nebulisation</li>
          <li><strong>Anticholinergic:</strong> Ipratropium bromide 0.5mg mixed with salbutamol nebulisers (repeat 4-6 hourly)</li>
        </ul>

        <p><strong>3. Corticosteroids:</strong></p>
        <ul>
          <li>Prednisolone 40-50mg PO immediately</li>
          <li>Or hydrocortisone 100mg IV if unable to take oral medication</li>
          <li>Continue for at least 5 days</li>
        </ul>

        <p><strong>4. Monitoring:</strong></p>
        <ul>
          <li>Continuous SpO₂ monitoring</li>
          <li>Peak flow before and after treatment</li>
          <li>Heart rate, respiratory rate, blood pressure</li>
          <li>Arterial blood gas if SpO₂ \&lt;92% or other features of life-threatening asthma</li>
        </ul>

        <p><strong>Second-Line Treatments (if not responding):</strong></p>
        <ul>
          <li><strong>Magnesium Sulphate:</strong> 1.2-2g IV infusion over 20 minutes</li>
          <li><strong>Aminophylline:</strong> Loading dose 5mg/kg IV over 20 minutes (if not on oral theophylline), then infusion</li>
          <li><strong>ICU referral:</strong> For consideration of intubation and mechanical ventilation</li>
        </ul>

        <p><strong>Subsequent Management:</strong></p>
        <ul>
          <li>Continue high-dose inhaled bronchodilators via nebuliser or spacer</li>
          <li>Continue oral prednisolone</li>
          <li>Monitor PEF and clinical features closely</li>
          <li>Chest X-ray to exclude pneumothorax, pneumonia, or other complications</li>
        </ul>

        <p><strong>Criteria for Hospital Admission:</strong></p>
        <ul>
          <li>Any feature of life-threatening asthma</li>
          <li>PEF \&lt;75% of predicted or best after initial treatment</li>
          <li>Previous near-fatal asthma or brittle asthma</li>
          <li>Presentation at night</li>
          <li>Pregnancy</li>
          <li>Recent hospital admission or ED attendance</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>3. What are the indications for ventilation?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p>Mechanical ventilation is indicated in acute severe asthma when medical management fails and the patient develops life-threatening features. The decision to intubate should be made early by experienced clinicians.</p>

        <p><strong>Absolute Indications:</strong></p>
        <ul>
          <li><strong>Respiratory arrest</strong></li>
          <li><strong>Cardiac arrest</strong></li>
          <li><strong>Severe hypoxemia:</strong> Despite maximal oxygen therapy</li>
          <li><strong>Reduced level of consciousness:</strong> Drowsiness, confusion, or coma</li>
          <li><strong>Respiratory exhaustion:</strong> Unable to maintain respiratory effort</li>
        </ul>

        <p><strong>Relative Indications:</strong></p>
        <ul>
          <li><strong>Rising PaCO₂:</strong> Especially with acidosis (pH &lt;7.2)</li>
          <li><strong>Hypoxemia:</strong> PaO₂ &lt;8 kPa (60 mmHg) despite high-flow oxygen</li>
          <li><strong>Deteriorating PEF:</strong> Despite aggressive treatment</li>
          <li><strong>Physical exhaustion:</strong> Patient unable to speak or becoming drowsy</li>
          <li><strong>Haemodynamic instability:</strong> Hypotension or arrhythmias</li>
        </ul>

        <p><strong>Important Considerations:</strong></p>
        <ul>
          <li>A normal or rising PaCO₂ in acute asthma is a concerning sign and may indicate impending respiratory failure</li>
          <li>Intubation and mechanical ventilation in severe asthma is difficult and carries significant risks including:
            <ul>
              <li>Barotrauma and pneumothorax</li>
              <li>Hypotension due to dynamic hyperinflation</li>
              <li>Difficulty achieving adequate ventilation due to high airway resistance</li>
            </ul>
          </li>
          <li>Use of non-invasive ventilation (NIV) is generally not recommended in acute severe asthma</li>
          <li>Senior anaesthetic and intensive care input should be sought early</li>
        </ul>

        <p><strong>Ventilation Strategy:</strong></p>
        <ul>
          <li>Use low tidal volumes (6-8 ml/kg)</li>
          <li>Allow permissive hypercapnia</li>
          <li>Prolonged expiratory time to prevent air trapping</li>
          <li>Monitor for complications including pneumothorax</li>
          <li>Continue aggressive medical therapy including bronchodilators and steroids</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>4. What is the evidence for long-acting β₂-agonists?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p>Long-acting β₂-agonists (LABAs) play an important role in the management of chronic asthma, but should never be used as monotherapy.</p>

        <p><strong>Evidence for Efficacy:</strong></p>
        <ul>
          <li><strong>Symptom Control:</strong> Multiple randomized controlled trials have shown that LABAs improve asthma symptoms, reduce nocturnal awakenings, and decrease the need for rescue bronchodilator use</li>
          <li><strong>Lung Function:</strong> LABAs produce significant improvements in FEV₁ and peak expiratory flow compared to placebo</li>
          <li><strong>Exacerbation Reduction:</strong> When combined with inhaled corticosteroids (ICS), LABAs reduce the frequency of asthma exacerbations</li>
          <li><strong>Quality of Life:</strong> Improvement in asthma-related quality of life scores</li>
        </ul>

        <p><strong>Types of LABAs:</strong></p>
        <ul>
          <li><strong>Salmeterol:</strong> Duration of action ~12 hours, twice daily dosing</li>
          <li><strong>Formoterol:</strong> Duration of action ~12 hours, twice daily dosing, faster onset of action than salmeterol</li>
          <li><strong>Vilanterol:</strong> Duration of action ~24 hours, once daily dosing</li>
        </ul>

        <p><strong>Combination Therapy:</strong></p>
        <ul>
          <li>LABAs should ALWAYS be prescribed in combination with ICS, never as monotherapy</li>
          <li>Combination ICS/LABA inhalers are preferred to ensure adherence</li>
          <li>Examples: Seretide (fluticasone/salmeterol), Symbicort (budesonide/formoterol), Relvar (fluticasone furoate/vilanterol)</li>
        </ul>

        <p><strong>Safety Concerns:</strong></p>
        <ul>
          <li>Early studies raised concerns about increased asthma-related deaths with LABA monotherapy</li>
          <li>These concerns led to black box warnings in some countries</li>
          <li>Subsequent evidence shows that when combined with ICS, LABAs are safe and reduce exacerbations</li>
          <li>The key principle is: <strong>Never prescribe LABAs without ICS</strong></li>
        </ul>

        <p><strong>Place in Therapy (Step-wise Approach):</strong></p>
        <ul>
          <li><strong>Step 3:</strong> Add LABA to low-moderate dose ICS if not controlled on ICS alone</li>
          <li>If no response to LABA after 4 weeks, consider stopping and increasing ICS dose or adding leukotriene receptor antagonist</li>
          <li>If good response but still not controlled, continue LABA and increase ICS dose</li>
        </ul>

        <p><strong>MART Therapy (Maintenance and Reliever Therapy):</strong></p>
        <ul>
          <li>Budesonide/formoterol can be used as both maintenance and reliever therapy</li>
          <li>Evidence shows this approach reduces exacerbations and improves symptom control</li>
          <li>Allows for flexible dosing in response to symptoms</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>5. Explain the mechanism of action for the following medications: ipratropium, salbutamol, and magnesium.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p>Each of these medications works through different mechanisms to produce bronchodilation in acute asthma:</p>

        <p><strong>1. Salbutamol (Short-Acting β₂-Agonist):</strong></p>
        <ul>
          <li><strong>Mechanism:</strong> Selective β₂-adrenoceptor agonist</li>
          <li><strong>Site of Action:</strong> β₂-adrenoceptors on bronchial smooth muscle</li>
          <li><strong>Cellular Action:</strong>
            <ul>
              <li>Binding to β₂-receptors activates adenylyl cyclase</li>
              <li>Increases intracellular cyclic AMP (cAMP)</li>
              <li>Increased cAMP activates protein kinase A</li>
              <li>Results in phosphorylation of proteins that regulate smooth muscle contraction</li>
              <li>Causes smooth muscle relaxation and bronchodilation</li>
            </ul>
          </li>
          <li><strong>Additional Effects:</strong>
            <ul>
              <li>Inhibits release of bronchoconstrictor mediators from mast cells</li>
              <li>Increases mucociliary clearance</li>
              <li>Reduces microvascular permeability</li>
            </ul>
          </li>
          <li><strong>Onset:</strong> 5 minutes when inhaled</li>
          <li><strong>Duration:</strong> 4-6 hours</li>
          <li><strong>Side Effects:</strong> Tachycardia, tremor, hypokalaemia (via β₂-receptor stimulation)</li>
        </ul>

        <p><strong>2. Ipratropium Bromide (Anticholinergic):</strong></p>
        <ul>
          <li><strong>Mechanism:</strong> Muscarinic receptor antagonist (M₁, M₂, and M₃ receptors)</li>
          <li><strong>Site of Action:</strong> Muscarinic receptors on bronchial smooth muscle</li>
          <li><strong>Cellular Action:</strong>
            <ul>
              <li>Blocks acetylcholine binding to muscarinic receptors</li>
              <li>Prevents vagally-mediated bronchoconstriction</li>
              <li>Blocks the pathway: vagal stimulation → acetylcholine release → M₃ receptor activation → smooth muscle contraction</li>
              <li>Reduces intracellular calcium, leading to bronchial smooth muscle relaxation</li>
            </ul>
          </li>
          <li><strong>Additional Effects:</strong>
            <ul>
              <li>Reduces mucus secretion</li>
              <li>Particularly effective for bronchospasm triggered by irritants or cold air</li>
            </ul>
          </li>
          <li><strong>Onset:</strong> 10-15 minutes when inhaled</li>
          <li><strong>Duration:</strong> 3-4 hours</li>
          <li><strong>Side Effects:</strong> Dry mouth, metallic taste (quaternary ammonium compound, minimal systemic absorption)</li>
          <li><strong>Synergy:</strong> Works synergistically with β₂-agonists as they target different pathways</li>
        </ul>

        <p><strong>3. Magnesium Sulphate:</strong></p>
        <ul>
          <li><strong>Mechanism:</strong> Multiple mechanisms producing bronchodilation</li>
          <li><strong>Primary Mechanisms:</strong>
            <ul>
              <li><strong>Calcium Channel Antagonism:</strong> Competes with calcium for entry into smooth muscle cells through voltage-gated calcium channels</li>
              <li>Reduced intracellular calcium decreases smooth muscle contraction</li>
              <li>Results in bronchial smooth muscle relaxation</li>
            </ul>
          </li>
          <li><strong>Secondary Mechanisms:</strong>
            <ul>
              <li>Inhibits acetylcholine release from nerve terminals</li>
              <li>Reduces histamine release from mast cells</li>
              <li>Stabilizes mast cell membranes</li>
              <li>May enhance the action of β₂-agonists</li>
              <li>Anti-inflammatory effects by reducing pro-inflammatory cytokines</li>
            </ul>
          </li>
          <li><strong>Dosing:</strong> 1.2-2g IV infusion over 20 minutes</li>
          <li><strong>Evidence:</strong> Most effective in severe asthma exacerbations (PEF \&lt;30% predicted)</li>
          <li><strong>Side Effects:</strong> Flushing, sensation of warmth, hypotension (usually mild), rarely respiratory depression with high doses</li>
          <li><strong>Monitoring:</strong> Blood pressure during infusion, check magnesium levels if renal impairment</li>
        </ul>

        <p><strong>Comparative Summary:</strong></p>
        <ul>
          <li><strong>First-line:</strong> Salbutamol (most rapid and potent bronchodilator)</li>
          <li><strong>Adjunct:</strong> Ipratropium (added to salbutamol in severe cases, different mechanism)</li>
          <li><strong>Second-line:</strong> Magnesium (reserved for severe/life-threatening asthma not responding to first-line treatment)</li>
        </ul>
      </div>
    </div>
  </div>

<!-- JavaScript -->  <script src="../js/firebase-config.js"></script>
  <script src="../js/dark-mode.js"></script>
  <script src="../js/auth.js"></script>
  <script src="../js/user-analytics.js"></script>
  <script src="../js/analytics-integration.js"></script>
  <script src="../js/completion-tracker.js"></script>
  <script src="../js/flag-tracker.js"></script>
  <script src="../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        }
      }
    }// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          }
        }, 100);
      }
    });
    }
  </script>

</body>
</html>
